Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $3.46 billion. The enterprise value is $4.44 billion.
| Market Cap | 3.46B |
| Enterprise Value | 4.44B |
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 48.04 million shares outstanding. The number of shares has decreased by -1.30% in one year.
| Current Share Class | 48.04M |
| Shares Outstanding | 48.04M |
| Shares Change (YoY) | -1.30% |
| Shares Change (QoQ) | -2.30% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 114.95% |
| Float | 47.46M |
Valuation Ratios
The trailing PE ratio is 21.77 and the forward PE ratio is 14.80. Haemonetics's PEG ratio is 1.04.
| PE Ratio | 21.77 |
| Forward PE | 14.80 |
| PS Ratio | 2.67 |
| Forward PS | 2.62 |
| PB Ratio | 4.23 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 24.31 |
| P/OCF Ratio | 19.05 |
| PEG Ratio | 1.04 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.47, with an EV/FCF ratio of 31.15.
| EV / Earnings | 26.46 |
| EV / Sales | 3.26 |
| EV / EBITDA | 12.47 |
| EV / EBIT | 17.96 |
| EV / FCF | 31.15 |
Financial Position
The company has a current ratio of 1.62, with a Debt / Equity ratio of 1.56.
| Current Ratio | 1.62 |
| Quick Ratio | 0.88 |
| Debt / Equity | 1.56 |
| Debt / EBITDA | 3.49 |
| Debt / FCF | 9.01 |
| Interest Coverage | 6.88 |
Financial Efficiency
Return on equity (ROE) is 18.83% and return on invested capital (ROIC) is 7.84%.
| Return on Equity (ROE) | 18.83% |
| Return on Assets (ROA) | 6.65% |
| Return on Invested Capital (ROIC) | 7.84% |
| Return on Capital Employed (ROCE) | 13.19% |
| Revenue Per Employee | $450,157 |
| Profits Per Employee | $55,468 |
| Employee Count | 3,023 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.71 |
Taxes
In the past 12 months, Haemonetics has paid $44.39 million in taxes.
| Income Tax | 44.39M |
| Effective Tax Rate | 20.93% |
Stock Price Statistics
The stock price has decreased by -15.40% in the last 52 weeks. The beta is 0.37, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | -15.40% |
| 50-Day Moving Average | 66.18 |
| 200-Day Moving Average | 71.95 |
| Relative Strength Index (RSI) | 63.79 |
| Average Volume (20 Days) | 527,873 |
Short Selling Information
The latest short interest is 4.12 million, so 8.57% of the outstanding shares have been sold short.
| Short Interest | 4.12M |
| Short Previous Month | 4.35M |
| Short % of Shares Out | 8.57% |
| Short % of Float | 8.68% |
| Short Ratio (days to cover) | 7.16 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.36 billion and earned $167.68 million in profits. Earnings per share was $3.31.
| Revenue | 1.36B |
| Gross Profit | 778.55M |
| Operating Income | 247.10M |
| Pretax Income | 146.99M |
| Net Income | 167.68M |
| EBITDA | 355.99M |
| EBIT | 247.10M |
| Earnings Per Share (EPS) | $3.31 |
Balance Sheet
The company has $308.07 million in cash and $1.28 billion in debt, giving a net cash position of -$975.28 million or -$20.30 per share.
| Cash & Cash Equivalents | 308.07M |
| Total Debt | 1.28B |
| Net Cash | -975.28M |
| Net Cash Per Share | -$20.30 |
| Equity (Book Value) | 820.84M |
| Book Value Per Share | 17.02 |
| Working Capital | 356.86M |
Cash Flow
In the last 12 months, operating cash flow was $181.73 million and capital expenditures -$39.28 million, giving a free cash flow of $142.45 million.
| Operating Cash Flow | 181.73M |
| Capital Expenditures | -39.28M |
| Free Cash Flow | 142.45M |
| FCF Per Share | $2.97 |
Margins
Gross margin is 57.21%, with operating and profit margins of 18.16% and 12.32%.
| Gross Margin | 57.21% |
| Operating Margin | 18.16% |
| Pretax Margin | 15.58% |
| Profit Margin | 12.32% |
| EBITDA Margin | 26.16% |
| EBIT Margin | 18.16% |
| FCF Margin | 10.47% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.30% |
| Shareholder Yield | 1.30% |
| Earnings Yield | 4.84% |
| FCF Yield | 4.11% |
Analyst Forecast
The average price target for Haemonetics is $99.78, which is 38.45% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $99.78 |
| Price Target Difference | 38.45% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Haemonetics has an Altman Z-Score of 2.75 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.75 |
| Piotroski F-Score | 5 |